Enabling Clinical Programs Through Antibody Glycosylation, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about antibody N- or O-linked glycosylation detection and engineering the identity and abundance of glycans during antibody manufacturing. Attendees will be introduced to functional examples on how glycosylations influence antibody immunogenicity and half-life. The featured speakers will discuss a promising case study on engineering IgG1 Fc as a cure for autoimmune diseases.
TORONTO, Aug. 14, 2024 /PRNewswire-PRWeb/ -- Antibody glycosylation: Effects, engineering and analysis
Therapeutic proteins produced in Chinese hamster ovary (CHO) cells commonly include post-translationally added N- or O-linked glycans that are critical quality attributes of drugs as they influence activity, immunogenicity, half-life and much more. Engineering the identity and abundance of the glycans on the therapeutic protein and analyzing the glycan distribution is often key for clinical success.
The sialylation of antibodies within the Fc domain (at ASN297) regulates the balance between inflammation and tolerance. Non-sialylated antibodies promote inflammation via activation of the Type I Fc receptors, whereas sialylated antibodies reduce inflammation and restore immune self-tolerance via activation of the Type II immunomodulatory Fc receptors DC-SIGN and CD23.
Patients with chronic autoimmune disease commonly present with the low circulating titers of sialylated antibodies, and therefore do not appropriately engage the Type II tolerizing Fc receptors. In this webinar, the expert speakers will discuss a novel therapeutic strategy for the treatment of autoimmune diseases and the administration of a recombinant human IgG1 Fc engineered to agonize the Type II Fc receptors to re-establish normal immune homeostasis.
In this webinar, the experts will also provide some background on how glycosylation is linked to modulating the immune system and how the glycosylation pathways can be engineered for a range of drug development effects, including increasing half-life and bioavailability, enhancing antibody-drug conjugate (ADC) effects and modulating the anti-inflammatory response.
Register for this webinar today to gain insights into the effects of glycosylation on drug efficacy and safety and how engineering glycan profiles can enhance clinical outcomes.
Join Bjørn Voldborg, Head of the National Biologics Facility, Technical University of Denmark (DTU); Greg Coffey, PhD, Co-Founder & Vice President, Immunology & Clinical Translational Research, Nuvig Therapeutics; and Divya Teja Vavilala, PhD, Head of Protein Analytics, ATUM, for the live webinar on Monday, September 9, 2024, at 10am EDT (2pm BST/UK).
For more information, or to register for this event, visit Enabling Clinical Programs Through Antibody Glycosylation.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com
View original content to download multimedia:https://www.prweb.com/releases/enabling-clinical-programs-through-antibody-glycosylation-upcoming-webinar-hosted-by-xtalks-302221988.html
SOURCE Xtalks
Upcoming Life Sciences Events
- October 2024
- Copenhagen: LSX Nordic Congress
- Basel: BiotechX Europe 2024
- Amsterdam: World Drug Safety Congress Europe
Latest company news
Syneos Health Appoints Costa Panagos as Chief Executive Officer